查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1969452

Granisetron市場：按劑型、產品類型、應用、通路和最終用戶分類－2026-2032年全球預測

Granisetron Market by Dosage Form, Product Type, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Granisetron市場價值將達到 79.5 億美元，到 2026 年將成長到 85 億美元，到 2032 年將達到 136.5 億美元，複合年成長率為 8.03%。

主要市場統計數據
基準年 2025 79.5億美元
預計年份：2026年 85億美元
預測年份 2032 136.5億美元
複合年成長率 (%) 8.03%

Granisetron的權威介紹：臨床機制、製劑演變及其對現代止吐療法的意義。

Granisetron是一種選擇性5-HT3受體拮抗劑，廣泛用於預防和治療化療、放療及術後護理相關的噁心和嘔吐。其臨床效用源自於其作用機制，即抑制胃腸道和中樞神經系統中由5-羥色胺介導的嘔吐訊號通路，使其成為一種重要的止吐藥物，其耐受性和療效對於患者的生活品質至關重要。隨著時間的推移，製劑的改進和臨床指南的更新，使得Granisetron的給藥途徑更加多樣化，涵蓋了從住院輸液室到門診手術和門診腫瘤診室等各種醫療環境。

不斷發展的臨床通訊協定、生產整合、更嚴格的監管以及分銷創新正在重塑Granisetron的環境。

Granisetron的現狀正受到臨床、監管和供應等多方面因素複雜相互作用的影響，這些因素正在改變止吐治療的格局。藥物科學的進步正在創造以患者為中心的治療選擇，例如分散劑和口服製劑，從而降低了門診治療的門檻。同時，隨著對多方面支持性治療的日益重視，腫瘤科和手術全期專科的通訊協定標準化也在不斷推進，這影響著處方模式和醫療服務提供者的用藥清單。

2025 年關稅調整對Granisetron採購、供應彈性和分銷連續性的營運影響評估。

到了2025年，累積政策調整、關稅調整和貿易措施相繼訂定，為全球藥品供應鏈帶來新的挑戰，影響著Granisetron的供應狀況和成本結構。跨境採購活性成分和最終劑型的生產商和經銷商正在評估多層關稅、複雜的海關程序以及潛在的報復性貿易措施的影響。這些變化促使企業重新審視籌資策略、合約條款和庫存緩衝，以應對不斷上漲的進口成本和海關延誤風險。

詳細的細分分析揭示了劑型、臨床應用、通路、終端用戶環境和產品類型如何影響Granisetron。

細分市場分析揭示了Granisetron的治療和商業性效用如何受到製劑形式、臨床應用、通路、終端用戶環境和產品類型的影響。依劑型分類包括注射劑、口溶錠和一般片劑。對於注射劑，臨床醫生可以選擇快速靜脈大劑量投藥或持續靜脈輸注，而片劑則方便門診患者使用。依臨床用途分類，格拉司瓊可分為化療引起的噁心嘔吐、術後噁心嘔吐和放療引起的噁心嘔吐。在化療引起的噁心嘔吐適應症中，區分急性期和延遲期會影響治療方法的選擇和聯合治療的確定。

本研究提供了醫療保健系統、監管差異和分銷基礎設施的區域概覽，並分析了主要地區在獲取Granisetron的差異。

區域趨勢對Granisetron在不同醫療體系中的生產、監管和應用起著決定性作用。在美洲，成熟的腫瘤科和手術全期護理實踐傾向於注射劑和口服劑型聯合使用，而採購則傾向於在成本效益和無菌供應的連續性之間取得平衡。報銷機制和醫院處方箋流程會影響格拉司瓊的採用率以及品牌藥和非專利藥之間的競爭程度，而集中採購協議則會對競標結果產生顯著影響。

從公司層級進行競爭和營運分析，重點關注製造能力、監管應對力和經銷夥伴關係，這些因素決定了Granisetron市場的主導。

Granisetron市場的競爭格局反映了成熟藥物研發公司、非專利生產商、無菌注射劑專業公司和分銷機構之間的平衡。藥物研發公司旨在提升品牌知名度和臨床認可度，因此傾向於投資於實證醫學研究和醫療專業人員培訓，以鞏固其市場地位。另一方面，非專利藥生產商則優先考慮生產效率、快速合規和價格競爭力，以確保與醫療機構簽訂合約。專門從事無菌注射劑生產的契約製造組織（CMO）在確保供應連續性方面發揮著至關重要的作用，尤其是在需要受控環境和檢驗的無菌製程生產的靜脈注射製劑方面。

為確保Granisetron的永續成功，提出切實可行的跨部門建議，以確保生產韌性、臨床差異化和分銷合作。

產業領導者應採取多管齊下的策略，整合臨床、生產和商業策略，以確保永續的競爭優勢。首先，應透過多地點合格評估、與專業無菌注射劑供應商建立策略合作夥伴關係以及製定正式的緊急應變計畫來增強生產韌性，以應對原料採購和物流中斷。同時，加大對品質系統和法規遵循的投入，將降低供應中斷風險，並保障所有劑型的產品品質。

採用穩健的混合方法研究途徑，結合對臨床醫師的訪談、監管審查、藥理學文獻和供應鏈分析，確保了實際可靠性。

本報告的研究整合透過結合一手和二手研究、監管文件、藥理學文獻以及相關人員訪談，確保了其可靠性和實用性。一手研究包括對臨床醫生、醫院藥劑師、採購專家和生產專家的訪談，以了解操作實踐、治療偏好和供應鏈限制。這些定性研究結果透過同行評審的臨床研究、產品專論和公開的監管文件進行三角檢驗，以檢驗臨床定位和生產方面的考慮。

一份權威的綜合分析報告，重點闡述了Granisetron的持續臨床意義，以及生產、分銷和循證應用方面的戰略要求。

Granisetron以其清晰的作用機制和可滿足多種臨床需求的靈活劑型，仍是現代止吐療法的基石。製劑創新、生產專業化和不斷發展的通路相互作用，為生產商、供應商和經銷商帶來了機會和營運挑戰。投資於強大的無菌生產能力、專注於從高價值臨床應用案例中獲取相關人員，並推廣符合醫院、診所和門診中心偏好的分銷策略的偏好相關者，將更有利於維持供應的連續性並展現其臨床價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：Granisetron市場（以劑型分類）

  • 注射藥物
    • 靜脈Bolus
    • 持續靜脈輸注
  • 口溶錠
  • 藥片
    • 標準

第9章：Granisetron市場：依產品類型分類

  • 品牌商品
  • 學名藥

第10章：Granisetron市場：依應用領域分類

  • 化療引起的噁心和嘔吐
    • 急性期
    • 後期
  • 術後噁心嘔吐
  • 放射治療引起的噁心和嘔吐

第11章Granisetron市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章Granisetron市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院

第13章Granisetron市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Granisetron市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章Granisetron市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國Granisetron市場

第17章：中國Granisetron市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-535C62918923

The Granisetron Market was valued at USD 7.95 billion in 2025 and is projected to grow to USD 8.50 billion in 2026, with a CAGR of 8.03%, reaching USD 13.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.95 billion
Estimated Year [2026] USD 8.50 billion
Forecast Year [2032] USD 13.65 billion
CAGR (%) 8.03%

Authoritative introduction to granisetron covering clinical mechanism, formulation evolution, and implications for modern antiemetic practice

Granisetron is a selective 5-HT3 receptor antagonist widely used to prevent and treat nausea and vomiting associated with chemotherapy, radiation, and postoperative care. Its clinical utility is grounded in a mechanism that blocks serotonin-mediated emetic signaling in the gastrointestinal tract and central nervous system, making it a mainstay in antiemetic regimens where tolerability and efficacy are critical considerations for patient quality of life. Over time, formulation innovation and shifting clinical guidelines have broadened how clinicians choose to administer granisetron across different care settings, from inpatient infusion suites to outpatient procedures and ambulatory oncology clinics.

Clinical adoption reflects a balance between evidence-based efficacy and practical delivery. Intravenous administration remains essential in acute care settings where rapid onset is required, while oral forms provide flexibility for ambulatory and home-based supportive care. The product lifecycle has been influenced by patent expirations and the entrance of generic formulations, which have altered procurement strategies for hospitals and pharmacies. In parallel, regulatory scrutiny around parenteral preparations and an increased emphasis on cold-chain integrity and sterility assurance have raised the bar for manufacturers and contract formulators.

Looking ahead, granisetron will continue to play an important role in multimodal antiemetic protocols, complemented by emerging agents and supportive therapies. Integration of real-world evidence and patient-reported outcomes is helping clinicians refine dosing and administration practices. As care shifts increasingly toward value-based delivery and outpatient treatment pathways, granisetron's various dosage forms and administration routes position it to remain a versatile component of contemporary antiemetic therapy.

How evolving clinical protocols, manufacturing consolidation, regulatory rigor, and distribution innovation are reshaping the granisetron landscape

The landscape for granisetron is being reshaped by a convergence of clinical, regulatory, and supply-side forces that together are driving transformative shifts in antiemetic care. Advances in formulation science have produced more patient-centric options, including dispersible and oral presentations that reduce barriers to outpatient treatment. At the same time, growing emphasis on multimodal supportive care has encouraged protocol standardization across oncology and perioperative specialties, affecting prescribing patterns and institutional formularies.

Supply chain dynamics and manufacturing consolidation are another powerful driver of change. Greater reliance on specialized sterile injectable capacity and contract manufacturing has heightened sensitivity to production disruptions, prompting organizations to diversify supplier relationships and to adopt more rigorous supplier qualification practices. Regulatory agencies have increased focus on manufacturing quality for parenteral products, elevating compliance costs and influencing which manufacturers can viably supply certain dosage forms.

Technological adoption is altering access and distribution channels. The rise of online pharmacies and integrated hospital distribution systems has expanded procurement choices for providers and patients, while telemedicine and remote care pathways have increased the demand for oral and patient-friendly dosing regimens. These disruptions are not isolated; they interact in compound ways, influencing clinical guideline evolution, payer decision-making, and the competitive positioning of branded versus generic products.

Assessing the operational consequences of 2025 tariff adjustments on pharmaceutical sourcing, supply resilience, and distribution continuity for granisetron

Cumulative policy shifts, tariff adjustments, and trade measures announced through 2025 have introduced new considerations for the global pharmaceutical supply chain that impact granisetron availability and cost structures. Manufacturers and distributors that source active pharmaceutical ingredients or finished dosage forms across borders are evaluating the implications of tariff layering, customs complexity, and potential retaliatory trade measures. These developments are prompting firms to reassess sourcing strategies, contract terms, and inventory buffers to manage exposure to incremental import costs and clearance delays.

As a result, companies are increasingly prioritizing supply chain resilience over minimal inventory models. This has led to a reassessment of regional manufacturing footprints and a stronger emphasis on nearshoring or diversified multisite production to reduce reliance on any single trade route. Procurement teams are renegotiating long-term supplier agreements to include clauses that address tariff pass-through and to secure alternative logistics arrangements. For clinical stakeholders, the immediate consequence is heightened vigilance around continuity of supply, particularly for sterile injectable preparations where manufacturing capacity is concentrated.

From an operational perspective, organizations are investing in customs expertise and trade compliance capabilities to mitigate the administrative burden of heightened tariff complexity. They are also accelerating digitalization of supply chain visibility tools to forecast shipment timing more accurately and to react more promptly to disruptions. Taken together, these measures are stabilizing supply for many stakeholders, but they also increase the fixed costs associated with distribution and inventory management. The landscape through 2025 underscores the need for integrated commercial, regulatory, and procurement strategies to preserve access and manage margin pressures without compromising product quality or patient care.

In-depth segmentation insights revealing how dosage form, clinical application, distribution route, end-user setting, and product type shape granisetron deployment

Segmentation analysis reveals how granisetron's therapeutic and commercial utility is shaped by formulation, clinical application, distribution pathways, end-user settings, and product type. Based on dosage form, the landscape comprises injection options, oral disintegrating tablets, and standard tablets; within injections, clinicians choose between rapid intravenous bolus administrations and controlled intravenous infusions, while tablet formats provide convenience for ambulatory care. Based on application, clinical use is categorized into chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, and radiation-induced nausea and vomiting; within chemotherapy-induced indications, differentiation between the acute phase and the delayed phase informs regimen selection and combination therapy choices.

Distribution channel segmentation distinguishes hospital pharmacies, online pharmacies, and retail pharmacies, each of which serves different procurement and fulfillment models and influences how products are stocked and dispensed. End-user segmentation includes ambulatory surgical centers, clinics, and hospitals, and each setting presents distinct operational needs for dosing flexibility, administration support, and inventory management. Product type segmentation differentiates branded and generic offerings, a dichotomy that shapes procurement behavior, formulary negotiations, and the emphasis on cost containment versus differentiated clinical value.

Understanding these intersecting segments is essential for stakeholders designing market entry strategies, optimizing product portfolios, or refining clinical engagement. Dosage-form choices influence clinical pathways and training needs, application-based segmentation directs evidence-generation priorities, and distribution-end-user dynamics determine logistical investments. Product type considerations ultimately affect pricing strategies, contracting approaches, and promotional focus, making segmentation insights pivotal for targeted commercialization and supply planning.

Regional overview linking healthcare systems, regulatory variability, and distribution infrastructures to differential granisetron access across major geographies

Regional dynamics play a decisive role in how granisetron is manufactured, regulated, and adopted across different healthcare systems. In the Americas, established oncology and perioperative practice patterns favor a mix of injectable and oral options, while procurement tends to balance cost efficiency with continuity of sterile supply. Reimbursement frameworks and hospital formulary processes influence uptake and the relative competitiveness of branded versus generic presentations, and centralized purchasing arrangements can significantly shape tender outcomes.

In Europe, Middle East & Africa, heterogeneity in regulatory pathways and healthcare infrastructure leads to diverse access models. High-income markets in Europe typically emphasize stringent manufacturing quality and demonstrate rapid adaptation to evidence-based guideline changes, whereas certain markets across the broader region may experience distribution friction or slower penetration of novel formulations due to logistical constraints or reimbursement hurdles. Localization of manufacturing and regulatory harmonization initiatives are important trends that affect how companies prioritize regional investments.

In Asia-Pacific, rapid expansion of oncology services and outpatient procedural capacity is driving demand for flexible dosing and user-friendly oral formulations. Robust contract manufacturing ecosystems in several countries support both domestic supply and export-oriented production, while variations in regulatory approval timelines and price sensitivity shape commercialization strategies. Across all regions, demographic shifts, evolving treatment protocols, and investments in healthcare infrastructure will continue to influence how granisetron is positioned clinically and commercially.

Competitive and operational company-level analysis highlighting manufacturing capability, regulatory strength, and distribution partnerships that determine granisetron leadership

Competitive dynamics in the granisetron landscape reflect a balance between incumbent originator companies, generic manufacturers, specialized sterile injectable producers, and distribution-focused organizations. Originator firms driving brand recognition and clinical awareness often invest in evidence generation and clinician education to preserve positioning, whereas generic manufacturers prioritize manufacturing efficiency, regulatory agility, and price competitiveness to capture institutional contracts. Contract manufacturing organizations that specialize in sterile parenteral processing play an outsized role in ensuring supply continuity, particularly for intravenous formulations that require controlled environment production and validated aseptic processes.

Distribution partners and hospital procurement teams exert meaningful influence on where spend is allocated, and strategic alliances between manufacturers and large healthcare systems can streamline formulary placement and shelf stocking. Companies that combine robust manufacturing capacity with strong regulatory track records and responsive supply chains tend to achieve preferred supplier status. Conversely, smaller players can find niches by focusing on patient-friendly oral disintegrating formulations or by providing tailored services such as ready-to-administer syringes and dose-specific presentations that reduce nursing preparation time.

Innovative commercial models, including outcome-based contracting for supportive care therapies and bundled procurement across health networks, are emerging as differentiators. Firms that demonstrate excellence in pharmacovigilance, real-world outcomes collection, and cold-chain logistics will be better positioned to meet the evolving expectations of payers, providers, and patients, and to secure long-term commercial relationships in an increasingly cost-conscious environment.

Practical, cross-functional recommendations to secure manufacturing resilience, clinical differentiation, and distribution alignment for sustained granisetron success

Industry leaders should adopt a multi-dimensional approach that synchronizes clinical, manufacturing, and commercial strategies to secure sustainable advantage. Begin by strengthening manufacturing resilience through multisite qualification, strategic partnerships with specialized sterile injectables providers, and formal contingency plans that address raw-material sourcing and logistics disruptions. Parallel investments in quality systems and regulatory compliance will reduce the risk of supply interruptions and protect product integrity across all dosage forms.

On the commercial front, prioritize evidence generation that addresses unmet clinical questions across key applications, especially differentiation in the acute and delayed phases of chemotherapy-induced nausea and vomiting. Tailor engagement efforts to the needs of hospitals, ambulatory surgical centers, and clinics, and align distribution strategies to the procurement preferences of each channel, including online pharmacies. Develop value propositions that articulate clinical benefits, nursing time savings, and total cost of care implications to support formulary inclusion and favorable contracting outcomes.

Finally, enhance collaboration across procurement, medical affairs, and supply chain teams to ensure alignment between commercial commitments and operational capacity. Build flexible contracting frameworks that account for trade policy volatility and tariff exposure, and invest in digital tools for inventory visibility and demand sensing. By integrating these measures, organizations can protect continuity of care for patients while pursuing growth and differentiation in a competitive antiemetic landscape.

Robust mixed-method research approach combining clinician interviews, regulatory review, pharmacological literature, and supply chain analysis to ensure actionable reliability

The research synthesis underpinning this report integrates primary and secondary evidence, regulatory documentation, pharmacological literature, and stakeholder interviews to ensure robustness and practical relevance. Primary research comprised interviews with clinicians, hospital pharmacists, procurement specialists, and manufacturing experts to capture operational realities, therapeutic preferences, and supply chain constraints. These qualitative insights were triangulated with peer-reviewed clinical studies, product monographs, and publicly available regulatory communications to validate clinical positioning and manufacturing considerations.

Secondary research encompassed a structured review of scientific literature, pharmacovigilance data, guideline recommendations from professional societies, and trade publications with a focus on formulation trends and distribution innovations. Supply chain and trade policy analysis drew on customs and logistics documentation, import-export notices, and industry guidance around tariff implementation to assess potential operational impacts. Throughout the process, findings were validated through iterative consultations with subject-matter experts to ensure that conclusions reflect current practice and foreseeable near-term developments.

Limitations of the methodology include the evolving nature of trade policies and regional regulatory decisions, which can shift rapidly and may alter operational implications. Nevertheless, the mixed-methods approach provides a defensible foundation for strategic decision-making by combining empirical evidence with practitioner experience and domain-specific knowledge.

Conclusive synthesis emphasizing granisetron's enduring clinical relevance coupled with strategic imperatives for manufacturing, distribution, and evidence-driven adoption

Granisetron remains a cornerstone of contemporary antiemetic therapy, supported by a clear mechanism of action and adaptable dosage forms that meet the needs of diverse clinical settings. The interplay between formulation innovation, manufacturing specialization, and distribution channel evolution is creating both opportunities and operational tensions for manufacturers, providers, and distributors. Stakeholders that invest in resilient sterile manufacturing capacity, evidence-generation focused on high-value clinical use cases, and distribution strategies tailored to the preferences of hospitals, clinics, and ambulatory centers will be best positioned to maintain supply continuity and to demonstrate clinical value.

Policy developments, including tariff adjustments and evolving regulatory expectations, demand proactive supply chain management and flexible contracting approaches. Regional nuances in healthcare infrastructure and reimbursement create differentiated pathways to adoption, making localized strategies essential. Overall, granisetron's established clinical role, combined with adaptable commercial approaches and a disciplined focus on manufacturing quality, supports continued relevance in antiemetic care as healthcare systems seek both clinical efficacy and operational efficiency.

In closing, stakeholders should view current dynamics as a prompt to strengthen cross-functional coordination, to accelerate patient-centered formulation development, and to codify supply continuity plans that safeguard patient care while enabling strategic growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Granisetron Market, by Dosage Form

  • 8.1. Injection
    • 8.1.1. Intravenous Bolus
    • 8.1.2. Intravenous Infusion
  • 8.2. Oral Disintegrating Tablet
  • 8.3. Tablet
    • 8.3.1. Standard

9. Granisetron Market, by Product Type

  • 9.1. Branded
  • 9.2. Generic

10. Granisetron Market, by Application

  • 10.1. Chemotherapy-Induced Nausea And Vomiting
    • 10.1.1. Acute Phase
    • 10.1.2. Delayed Phase
  • 10.2. Postoperative Nausea And Vomiting
  • 10.3. Radiation-Induced Nausea And Vomiting

11. Granisetron Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Granisetron Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Granisetron Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Granisetron Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Granisetron Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Granisetron Market

17. China Granisetron Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Cipla Limited
  • 18.6. Dr. Reddy's Laboratories Limited
  • 18.7. F. Hoffmann-La Roche Ltd
  • 18.8. Fresenius Kabi AG
  • 18.9. Glenmark Pharmaceuticals Limited
  • 18.10. Hikma Pharmaceuticals PLC
  • 18.11. Sandoz International GmbH
  • 18.12. Sun Pharmaceutical Industries Limited
  • 18.13. Teva Pharmaceutical Industries Limited
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GRANISETRON MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GRANISETRON MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GRANISETRON MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS BOLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GRANISETRON MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GRANISETRON MARKET SIZE, BY ORAL DISINTEGRATING TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GRANISETRON MARKET SIZE, BY STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GRANISETRON MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GRANISETRON MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GRANISETRON MARKET SIZE, BY ACUTE PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GRANISETRON MARKET SIZE, BY DELAYED PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GRANISETRON MARKET SIZE, BY POSTOPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GRANISETRON MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GRANISETRON MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GRANISETRON MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GRANISETRON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GRANISETRON MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GRANISETRON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GRANISETRON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS GRANISETRON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GRANISETRON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. GCC GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 154. GCC GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 179. G7 GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 181. G7 GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. NATO GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. NATO GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 190. NATO GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL GRANISETRON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA GRANISETRON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA GRANISETRON MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA GRANISETRON MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA GRANISETRON MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA GRANISETRON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA GRANISETRON MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA GRANISETRON MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA GRANISETRON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA GRANISETRON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)